REV7 suppression also sensitizes malignant melanoma, TGCT, and colon cancer cells to cisplatin, doxorubicin, or oxaliplatin, and sensitizes gliomas and esophageal squamous cell carcinoma (SCC) cells to IR [86,90,91,101]. Here, MAD2L2 is linked to esophageal squamous cell carcinoma.